ION717 trial re-opens with 3rd dosing regimen

This morning Ionis Pharmaceuticals announced that PrProfile ( NCT06153966 ), their Phase 1/2a trial of ION717, a PrP-lowering antisense oligonucleotide for symptomatic prion disease patients, has re-opened. background If you’re just tuning in now, here’s a bit of background. ION717 is the first PrP-lowering drug ever tested in humans. PrP lowering has a strong scientific foundation , because PrP…